Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Amgen Inc.


Business: Biopharmaceuticals

AMGN's licensing deal for rights to Novo Nordisk's version of thrombopoietin strengthens the Thousand Oaks, Calif., company's patent position if and when it meets

Genentech Inc.

in patent court over rights to

Read the full 386 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers